Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based Lallemand Pharma and GM Pharmaceuticals have introduced a new oral vaccine Polyvalent Mechanical Bacterial Lysates (PMBL) in Georgia, US.
Subscribe to our email newsletter
PMBL are used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree, in addition to acute exacerbations in chronic obstructive pulmonary disease (COPD).
The PMBL, prepared from a large array of inactivated pathogenic bacteria via mechanical lysis, will be sold under the brand name Ismigen.
Lallemand specializes in yeast, bacteria and yeast derivatives, for animal nutrition, baking, winemaking and pharmaceutical industries.